These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 37094132)

  • 21. Renal inflammation: targeted iron oxide nanoparticles for molecular MR imaging in mice.
    Serkova NJ; Renner B; Larsen BA; Stoldt CR; Hasebroock KM; Bradshaw-Pierce EL; Holers VM; Thurman JM
    Radiology; 2010 May; 255(2):517-26. PubMed ID: 20332377
    [TBL] [Abstract][Full Text] [Related]  

  • 22. IOP Injection, A Novel Superparamagnetic Iron Oxide Particle MRI Contrast Agent for the Detection of Hepatocellular Carcinoma: A Phase II Clinical Trial.
    Chiang CF; Hsu YH; Hsieh WY; Liao TH; Chen CL; Chen YC; Liang PC; Wang SJ
    J Magn Reson Imaging; 2023 Oct; 58(4):1177-1188. PubMed ID: 36773005
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular magnetic resonance imaging of activated hepatic stellate cells with ultrasmall superparamagnetic iron oxide targeting integrin αvβ₃ for staging liver fibrosis in rat model.
    Zhang C; Liu H; Cui Y; Li X; Zhang Z; Zhang Y; Wang D
    Int J Nanomedicine; 2016; 11():1097-108. PubMed ID: 27051285
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeted dual-contrast T1- and T2-weighted magnetic resonance imaging of tumors using multifunctional gadolinium-labeled superparamagnetic iron oxide nanoparticles.
    Yang H; Zhuang Y; Sun Y; Dai A; Shi X; Wu D; Li F; Hu H; Yang S
    Biomaterials; 2011 Jul; 32(20):4584-93. PubMed ID: 21458063
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tuning the relaxation rates of dual-mode T(1)/T(2) nanoparticle contrast agents: a study into the ideal system.
    Keasberry NA; Bañobre-López M; Wood C; Stasiuk GJ; Gallo J; Long NJ
    Nanoscale; 2015 Oct; 7(38):16119-28. PubMed ID: 26371437
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ultrasmall superparamagnetic iron oxide (USPIO)-based liposomes as magnetic resonance imaging probes.
    Frascione D; Diwoky C; Almer G; Opriessnig P; Vonach C; Gradauer K; Leitinger G; Mangge H; Stollberger R; Prassl R
    Int J Nanomedicine; 2012; 7():2349-59. PubMed ID: 22661890
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enhancement of liver hemangiomas on T1-weighted MR SE images by superparamagnetic iron oxide particles.
    Grangier C; Tourniaire J; Mentha G; Schiau R; Howarth N; Chachuat A; Grossholz M; Terrier F
    J Comput Assist Tomogr; 1994; 18(6):888-96. PubMed ID: 7962795
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Magnetic resonance imaging of hepatic focal lesions: dynamic contrastographic evaluation with gadolinium versus reticulo-endothelial hepato-specific contrast media].
    Di Cesare E; Cariello G; Barile A; Sabatini M; Michelini O; Erriquez D; Masciocchi C
    Radiol Med; 2000 Oct; 100(4):245-50. PubMed ID: 11155451
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gold-coated iron oxide nanoparticles as a T2 contrast agent in magnetic resonance imaging.
    Ahmad T; Bae H; Rhee I; Chang Y; Jin SU; Hong S
    J Nanosci Nanotechnol; 2012 Jul; 12(7):5132-7. PubMed ID: 22966533
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ring enhancement in ultrasmall superparamagnetic iron oxide MR imaging: a potential new sign for characterization of liver lesions.
    Mergo PJ; Helmberger T; Nicolas AI; Ros PR
    AJR Am J Roentgenol; 1996 Feb; 166(2):379-84. PubMed ID: 8553952
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Heterogeneous Iron Oxide/Dysprosium Oxide Nanoparticles Target Liver for Precise Magnetic Resonance Imaging of Liver Fibrosis.
    Balachandran YL; Wang W; Yang H; Tong H; Wang L; Liu F; Chen H; Zhong K; Liu Y; Jiang X
    ACS Nano; 2022 Apr; 16(4):5647-5659. PubMed ID: 35312295
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Magnetic resonance imaging of focal liver lesions. Comparison of the superparamagnetic iron oxide resovist versus gadolinium-DTPA in the same patient.
    Vogl TJ; Hammerstingl R; Schwarz W; Kümmel S; Müller PK; Balzer T; Lauten MJ; Balzer JO; Mack MG; Schimpfky C; Schrem H; Bechstein WO; Neuhaus P; Felix R
    Invest Radiol; 1996 Nov; 31(11):696-708. PubMed ID: 8915751
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Engineering manganese ferrite shell on iron oxide nanoparticles for enhanced T
    Li M; Bao J; Zeng J; Huo L; Shan X; Cheng X; Qiu D; Miao W; Zhu X; Huang G; Ni K; Zhao Z
    J Colloid Interface Sci; 2022 Nov; 626():364-373. PubMed ID: 35797871
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Detection and characterization of focal liver lesions using superparamagnetic iron oxide-enhanced magnetic resonance imaging: comparison between ferumoxides-enhanced T1-weighted imaging and delayed-phase gadolinium-enhanced T1-weighted imaging.
    Takahama K; Amano Y; Hayashi H; Ishihara M; Kumazaki T
    Abdom Imaging; 2003; 28(4):525-30. PubMed ID: 14580096
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Iron oxide nanoparticles stabilized with dendritic polyglycerols as selective MRI contrast agents.
    Nordmeyer D; Stumpf P; Gröger D; Hofmann A; Enders S; Riese SB; Dernedde J; Taupitz M; Rauch U; Haag R; Rühl E; Graf C
    Nanoscale; 2014 Aug; 6(16):9646-54. PubMed ID: 24991655
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A new class of cubic SPIONs as a dual-mode T1 and T2 contrast agent for MRI.
    Alipour A; Soran-Erdem Z; Utkur M; Sharma VK; Algin O; Saritas EU; Demir HV
    Magn Reson Imaging; 2018 Jun; 49():16-24. PubMed ID: 28958878
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeted MR Imaging Adopting T1-Weighted Ultra-Small Iron Oxide Nanoparticles for Early Hepatocellular Carcinoma: An
    Xu YH; Yang J; Meng J; Wang H
    Chin Med Sci J; 2020 Jun; 35(2):142-150. PubMed ID: 32684234
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Optimization of molecularly targeted MRI in the brain: empirical comparison of sequences and particles.
    Zarghami N; Khrapitchev AA; Perez-Balderas F; Soto MS; Larkin JR; Bau L; Sibson NR
    Int J Nanomedicine; 2018; 13():4345-4359. PubMed ID: 30100719
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increased transverse relaxivity in ultrasmall superparamagnetic iron oxide nanoparticles used as MRI contrast agent for biomedical imaging.
    Mishra SK; Kumar BS; Khushu S; Tripathi RP; Gangenahalli G
    Contrast Media Mol Imaging; 2016 Sep; 11(5):350-361. PubMed ID: 27230705
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New strategies to prolong the in vivo life span of iron-based contrast agents for MRI.
    Antonelli A; Sfara C; Battistelli S; Canonico B; Arcangeletti M; Manuali E; Salamida S; Papa S; Magnani M
    PLoS One; 2013; 8(10):e78542. PubMed ID: 24223101
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.